CRISPR cell and gene therapy have been designed largely with respect to a single reference human genome. A new study reveals how human genetic diversity could lead to off-target effects and presents a new tool to identify these risks.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Graham, F. Nature https://doi.org/10.1038/d41586-020-01928-y (2020).
Science News Staff. Science https://doi.org/10.1126/science.adf7363 (2022).
Cancellieri, S. et al. Nat. Genet. https://doi.org/10.1038/s41588-022-01257-y (2022).
Sinha, D. et al. Am. J. Hum. Genet. 107, 278–292 (2020).
Keough, K. C. et al. Genome Biol. 20, 167 (2019).
Saha, K. et al. Nature 592, 195–204 (2021).
Misek, S. A. et al. Preprint at bioRxiv https://doi.org/10.1101/2022.11.18.517155 (2022).
Lessard, S. et al. Proc. Natl Acad. Sci. USA 114, E11257–E11266 (2017).
Scott, D. A. & Zhang, F. Nat. Med. 23, 1095–1101 (2017).
Leibowitz, M. L. et al. Nat. Genet. 53, 895–905 (2021).
Maeder, M. L. et al. Nat. Med. 25, 229–233 (2019).
Musunuru, K. et al. Nature 593, 429–434 (2021).
Foy, S. P. et al. Nature https://doi.org/10.1038/s41586-022-05531-1 (2022).
Center for Biologics Evaluation and Research. Human Gene Therapy Products Incorporating Human Genome Editing (U.S. Food and Drug Administration, 2022).
Acknowledgements
K.S. has received funding from the US National Science Foundation, grant nos. EEC-1648035 and AWD-101645-G3/RJ375-G3, and the US National Institutes for Health, grant nos. R35GM119644, U01EY032333 and UH3NS111688.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.S. receives sponsored research support from Spotlight Therapeutics and Synthego and is an advisor to Notch Therapeutics and Andson Biotech.
Rights and permissions
About this article
Cite this article
Saha, K. Accounting for diversity in the design of CRISPR-based therapeutic genome editing. Nat Genet 55, 6–7 (2023). https://doi.org/10.1038/s41588-022-01272-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41588-022-01272-z